Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $59.1 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.